Crohns logo
  Home | About Us | More Info | Articles | Archive | Product List | Store Map | SEARCH | Site Map | Why Shop
Safe Shopping Guaranteed100% Secure     Call in Your Order Mon - Fri 9AM to 5PM PST1-877-240-7528 Contact Us by e-mail Have Questions. Check out Help!Help View items in your basket Basket Shiping FAQShipping FAQ

Crohn's Disease- Pathophysiology and Conventional and Alternative Treatment Options

Crohn's Disease

Table 1: Subcategories of Crohn's Disease

Table 2: Signs and Symptoms of Crohn's Disease and Ulcerative Colitis

Risk Factors



    The Genetic Component of Crohn's Disease

    Stress in the Etiology of Crohn's Disease

    Microbial Factors

    Inflammation/Immune Response

    Intestinal Permeability

    Other Abnormalities Contributing to the Etiopathogenesis of Crohn's Disease

Conventional Treatment of Crohn's Disease

Table 5: Conventional Medications and their Mechanisms in Crohn's Disease

Nutrient Deficiences in Crohn's Disease

Table 6: nutrient Deficiencies Associated with Crohn's Disease

Dietary Interventions in Crohn's Disease

Table 7: Diet Therapies Compared to Steroid Medications in Crohn's Disease

Probiotics in the Treatment of Crohn's Disease

Fatty Acids for the Treatment of Crohn's Disease

Table 8: A Summary of Omega-3 Fatty Acid Studies in Crohn's Disease


N-acetyl Glucosamine

Remicade Increasing Risk of Cancer

Botanicals in the Treatment of Crohn's Disease

Dehydroepiandrosterone (DHEA)

Potential Sequelae of Crohn's Disease



1. Crohns and Colitis Foundation of America, Inc. 2004. aboutcd

2. Motil KJ, Grand RJ. Nutritional management of inflammatory bowel disease. Pediatr Clin North Am 1985;32:447-469.

3. Sonnenberg A, McCarty DJ, Jacobsen SJ. Geographic variation of inflammatory bowel disease within the United States. Gastroenterology1991;100:143-149.

4. Somerville KW, Logan RF, Edmond M, Langman MJ. Smoking and Crohns disease.Br Med J (Clin Res Ed) 1984;289:954-956.

5. Cottone M, Rosselli M, Orlando A, et al. Smoking habits and recurrence in Crohns disease. Gastroenterology 1994;106:643-648.

6. Lindberg E, Jarnerot G, Huitfeldt B. Smoking in Crohns disease: effect on localisation and clinical course. Gut 1992;33:779-782.

7. Lashner BA, Shaheen NJ, Hanauer SB, Kirschner BS. Passive smoking is associated with an increased risk of developing inflammatory bowel disease in children. Am J Gastroenterol 1993;88:356-359.

8. Persson PG, Ahlbom A, Hellers G. Inflammatory bowel disease and tobacco smoke - a case-control study. Gut 1990;31:1377-1381.

9. Gilat T, Hacohen D, Lilos P, Langman MJ. Childhood factors in ulcerative colitis and Crohns disease. An international cooperative study. Scand J Gastroenterol 1987;22:1009- 1024.

10. Wurzelmann JI, Lyles CM, Sandler RS. Childhood infections and the risk of inflammatory bowel disease. Dig Dis Sci 1994;39:555- 560.

11. Card T, Logan RF, Rodrigues LC, Wheeler JG. Antibiotic use and the development of Crohn’s disease. Gut 2004;53:246-250.

12. Godet PG, May GR, Sutherland LR. Metaanalysis of the role of oral contraceptive agents in inflammatory bowel disease. Gut1995;37:668-673.

13. Alstead EM. The pill: safe sex and Crohn’s disease? Gut 1999;45:165-166.

14. Bielecki JW, Filippini L. Side effects of nonsteroidal antirheumatic agents in the lower intestinal tract. Schweiz Med Wochenschr1993;123:1419-1428. [Article in German]

15. Banerjee AK, Peters TJ. Crohns disease and NSAID enteropathy - a unifying model.Gastroenterology 1990;99:1190-1192.

16. Felder JB, Korelitz BI, Rajapakse R, et al. Effects of nonsteroidal antiinflammatory drugs on inflammatory bowel disease: a case-control study. Am J Gastroenterol 2000;95:1949-1954.

17. Kurina LM, Goldacre MJ, Yeates D, Seagroatt V. Appendicectomy, tonsillectomy, and inflammatory bowel disease: a case-control record linkage study. J Epidemiol Community Health 2002;56:551-554.

18. Frisch M, Gridley G. Appendectomy in adulthood and the risk of inflammatory bowel diseases. Scand J Gastroenterol 2002;37:1175- 1177.

19. Morris DL, Montgomery SM, Galloway ML, et al. Inflammatory bowel disease and laterality: is left handedness a risk? Gut 2001;49:199-202.

20. Persson PG, Ahlbom A. Relative risk is a relevant measure of association of lefthandedness with inflammatory bowel disease.Neuropsychologia 1988;26:737-740.

21. Lashner BA. The Cleveland Clinic Disease Management Project: Inflammatory Bowel Disease. June 17, 2004. http:// diseasemanagement/gastro/inflammatory bowel/inflammatory bowel1.htm

22. Ge ZZ, Hu YB, Xiao SD. Capsule endoscopy in diagnosis of small bowel Crohns disease.World J Gastroenterol 2004;10:1349-1352.

23. Shafran I, Piromalli C, Decker JW, et al. Seroreactivities against Saccharomyces cerevisiae and Mycobacterium avium subsp. paratuberculosis p35 and p36 antigens in Crohns disease patients. Dig Dis Sci 2002;47:2079-2081.

24. Best WR, Becktel JM, Singleton JW, Kern F Jr. Development of a Crohns disease activity index, National Cooperative Crohn's Disease Study. Gastroenterology 1976;70:439-444.

25. Winship DH, Summers RW, Singleton JW, et al. National Cooperative Crohn's Disease Study: study design and conduct of the study.Gastroenterology 1979;77:829-842.

26. Hyams JS, Ferry GD, Mandel FS, et al. Development and validation of a pediatric Crohns disease activity index. J Pediatr Gastroenterol Nutr 1991;12:439-447.

27. Ogura Y, Bonen DK, Inohara N, et al. A frameshift mutation in NOD2 associated with susceptibility to Crohns disease. Nature 2001;411:603-606.

28. Hampe J, Cuthbert A, Croucher PJ, et al. Association between insertion mutation in NOD2 gene and Crohn's disease in German and British populations. Lancet 2001;357:1925-1928.

29. Armuzzi A, Ahmad T, Ling KL, et al. Genotype- phenotype analysis of the Crohns disease susceptibility haplotype on chromosome 5q31.Gut 2003;52:1133-1139.

30. Peltekova VD, Wintle RF, Rubin LA, et al. Functional variants of OCTN cation transporter genes are associated with Crohn disease.Nat Genet 2004;36:471-475.

31. Stoll M, Corneliussen B, Costello CM, et al. Genetic variation in DLG5 is associated with inflammatory bowel disease. Nat Genet 2004;36:476-480.

32. Rosenstiel P, Fantini M, Brautigam K, et al. TNF-alpha and IFN-gamma regulate the expression of the NOD2 (CARD15) gene in human intestinal epithelial cells. Gastroenterology 2003;124:1001-1009.

33. Hisamatsu T, Suzuki M, Reinecker HC, et al. CARD15/NOD2 functions as an antibacterial factor in human intestinal epithelial cells.Gastroenterology 2003;124:993-1000.

34. Heresbach D, Gicquel-Douabin V, Birebent B, et al. NOD2/CARD15 gene polymorphisms in Crohn disease: a genotype-phenotype analysis. Eur J Gastroenterol Hepatol 2004;16:55-62.

35. Rioux JD, Daly MJ, Silverberg MS, et al. Genetic variation in the 5q31 cytokine gene cluster confers susceptibility to Crohn disease.Nat Genet 2001;29:223-228.

36. Franchimont D, Vermeire S, El Housni H, et al. Deficient host-bacteria interactions in inflammatory bowel disease? The toll-like receptor (TLR)-4 Asp299gly polymorphism is associated with Crohns disease and ulcerative colitis. Gut 2004;53:987-992.

37. Mozsik G, Nagy Z, Nagy A, et al. Leiden mutation (as genetic) and environmental (retinoids) sequences in the acute and chronic inflammatory and premalignant colon disease in human gastrointestinal tract. J Physiol Paris 2001;95:489-494.

38. Nagy Z, Nagy A, Karadi O, et al. Prevalence of the factor V Leiden mutation in human inflammatory bowel disease with different activity. J Physiol Paris 2001;95:483-487.

39. Collins SM. Stress and the gastrointestinal tract IV. Modulation of intestinal inflammation by stress: basic mechanisms and clinical relevance. Am J Physiol Gastrointest Liver Physiol 2001;280:G315-G318.

40. Hollander D. Intestinal permeability, leaky gut, and intestinal disorders. Curr Gastroenterol Rep 1999;1:410-416.

41. Kawahito Y, Sano H, Kawata M, et al. Local secretion of corticotropin-releasing hormone by enterochromaffin cells in human colon.Gastroenterology 1994;106:859-865.

42. Kiliaan AJ, Saunders PR, Bijlsma PB, et al. Stress stimulates transepithelial macromolecular uptake in rat jejunum. Am J Physiol 1998;275:G1037-G1044.

43. Cabarrocas J, Savidge TC, Liblau RS. Role of enteric glial cells in inflammatory bowel disease. Glia 2003;41:81-93.

44. Mardini HE, Kip KE, Wilson JW. Crohns disease: a two-year prospective study of the association between psychological distress and disease activity. Dig Dis Sci 2004;49:492-497.

45. Mittermaier C, Dejaco C, Waldhoer T, et al. Impact of depressive mood on relapse in patients with inflammatory bowel disease: a prospective 18-month follow-up study.Psychosom Med 2004;66:79-84.

46. Sartor RB. Enteric microflora in IBD: pathogens or commensals? Inflamm Bowel Dis 1997;3:230-235.

47. Darfeuille-Michaud A, Neut C, Barnich N, et al. Presence of adherent Eschericia coli strains in ileal mucosa of patients with Crohn’s disease. Gastroenterology 1998;115;1405- 1413.

48. Hollander D, Vadheim CM, Brettholz E, et al. Increased intestinal permeability in patients with Crohn disease and their relatives. A possible etiologic factor. Ann Intern Med 1986;105:883-885.

49. Ibbotson JP, Lowes JR, Chahal H, et al. Mucosal cell-mediated immunity to mycobacterial, enterobacterial, and other microbial antigens in inflammatory bowel disease. Clin Exp Immunol 1992;87:224-230.

50. Martin HM, Campbell BJ, Hart CA, et al. Enhanced Escherichia coli adherence and invasion in Crohn disease and colon cancer.Gastroenterology 2004;127:80-93.

51. Chen W, Li D, Paulus B, et al. Detection of Listeria monocytogenes by polymerase chain reaction in intestinal mucosal biopsies from patients with inflammatory bowel disease and controls. J Gastroenterol Hepatol 2000;15:1145-1150.

52. Lamps LW, Madhusudhan KT, Havens JM, et al. Pathogenic Yersinia DNA is detected in bowel and mesenteric lymph nodes from patients with Crohn disease. Am J Surg Pathol 2003;27:220-227.

53. Greenwood MH. Human carriage of Yersinia species and incidence in foods. Contrib Microbiol Immunol 1995;13:74-76.

54. Chiba M, Fukushima T, Inoue S, et al. Listeria monocytogenes in Crohn disease. Scand J Gastroenterol 1998;33:430-434.

55. Hugot JP, Alberti C, Berrebi D, et al. Crohn’s disease: the cold chain hypothesis. Lancet2003;362:2012-2015.

57. Iizuka M, Nakagomi O, Chiba M, et al. Absence of measles virus in Crohns disease.Lancet 1995;345:199.

58. Johne HA, Frothingham L. Ein eigentuemlicher fall von tuberkulose beim rind. Deutsche Zeitschrift fur Tiermedicin und Pathologie 1895;21:438-454. [Article in German]

59. Dalziel TK. Chronic interstitial enteritis. Br Med J 1913;ii:1068-1070.

60. Chiodini RJ, Van Kruiningen HJ, Merkal RS, et al. Characteristics of an unclassified Mycobacterium species isolated from patients with Crohns disease. J Clin Microbiol 1984;20:966-971.

61. Chiodini RJ, Van Kruiningen HJ, Thayer WR, et al. Possible role of mycobacteria in inflammatory bowel disease. I. An unclassified Mycobacterium species isolated from patients with Crohns disease. Dig Dis Sci 1984;29:1073-1079.

62. Sanderson JD, Moss MT, Tizard ML, Hermon- Taylor J. Mycobacterium paratuberculosisDNA in Crohns disease tissue. Gut 1992;33:890-896.

63. Fidler HM, Thurrell W, Johnson NM, et al. Specific detection of Mycobacterium paratuberculosisDNA associated with granulomatous tissue in Crohn’s disease. Gut 1994;35:506-510.

64. Millar D, Ford J, Sanderson J, et al. IS900 PCR to detect Mycobacterium paratuberculosis in retail supplies of whole pasteurized cows' milk in England and Wales. Appl Environ Microbiol 1996;62:3446-3452.

65. Corti S, Stephan R. Detection of Mycobacterium avium subspecies paratuberculosisspecific IS900 insertion sequences in bulk-tank milk samples obtained from different regions throughout Switzerland. BMC Microbiol2002;2:15.

66. Hermon-Taylor J, Bull TJ, Sheridan JM, et al. Causation of Crohn’s disease by Mycobacterium avium subspecies paratuberculosis. Can J Gastroenterol 2000;14:521-539.

67. Bull TJ, McMinn EJ, Sidi-Boumedine K, et al. Detection and verification of Mycobacterium avium subsp. paratuberculosis in fresh ileocolonic mucosal biopsy specimens from individuals with and without Crohn’s disease.J Clin Microbiol 2003;41:2915-2923.

68. Naser SA, Ghobrial G, Romero C, Valentine JF. Culture of Mycobacterium avium subspeciesparatuberculosis from the blood of patients with Crohn’s disease. Lancet 2004;364:1039-1044.

69. Ross J. Control of messenger RNA stability in higher eukaryotes. Trends Genet 1996;12:171- 175.

70. Hulten K, El-Zimaity HM, Karttunen TJ, et al. Detection of Mycobacterium avium subspeciesparatuberculosis in Crohn’s diseased tissues by in situ hybridization. Am J Gastroenterol 2001;96:1529-1535.

71. Jarnerot G, Rolny P, Wickbom G, Alemayehu G. Antimycobacterial therapy ineffective in Crohn’s disease after a year. Lancet 1989;1:164-165.

72. Hampson SJ, Parker MC, Saverymuttu SH, et al. Results of quadruple antimycobacterial chemotherapy in 17 Crohn’s disease patients completing six months treatment. Gastroenterology 1988;94:170.

73. Prantera C, Kohn A, Mangiarotti R, et al. Antimycobacterial therapy in Crohn’s disease: results of a controlled, double-blind trial with a multiple antibiotic regimen. Am J Gastroenterol 1994;89:513-518.

74. Thomas GA, Swift GL, Green JT, et al. Controlled trial of antituberculous chemotherapy in Crohn’s disease: a five year follow up study. Gut 1998;42:497-500.

75. Gui GP, Thomas PR, Tizard ML, et al. Twoyear- outcomes analysis of Crohn’s disease treated with rifabutin and macrolide antibiotics.J Antimicrob Chemother 1997;39:393-400.

76. Douglass A, Cann PA, Bramble MG. An open pilot study of antimicrobial therapy in patients with unresponsive Crohn’s disease. Gut 2000;46:A11.

77. Shafran I, Kugler L, El-Zaatari FA, et al. Open clinical trial of rifabutin and clarithromycin therapy in Crohn’s disease. Dig Liver Dis2002;34:22-28.

78. Borody TJ, Leis S, Warren EF, Surace R. Treatment of severe Crohn’s disease using antimycobacterial triple therapy -- approaching a cure? Dig Liver Dis 2002;34:29-38.

79. Brandtzaeg P. Inflammatory bowel disease: clinics and pathology. Do inflammatory bowel disease and periodontal disease have similar immunopathogeneses? Acta Odontol Scand 2001;59:235-243.

80. Vermeire S, Rutgeerts P. Antibody responses in Crohn’s disease. Gastroenterology2004;126:601-604.

81. MacPherson A, Khoo UY, Forgacs I, et al. Mucosal antibodies in inflammatory bowel disease are directed against intestinal bacteria.Gut 1996;38:365-375.

82. Zareie M, Singh PK, Irvine EJ, et al. Monocyte/ macrophage activation by normal bacteria and bacterial products: implications for altered epithelial function in Crohn’s disease. Am J Pathol 2001;158:1101-1109.

83. MacDonald TT, Murch SH. Aetiology and pathogenesis of chronic inflammatory bowel disease. Baillieres Clin Gastroenterol 1994;8:1-34.

84. Dohi T, Fujihashi K, Kiyono H, et al. Mice deficient in Th1- and Th2-type cytokines develop distinct forms of hapten-induced colitis. Gastroenterology 2000;119:724-733.

85. Iqbal N, Oliver JR, Wagner FH, et al. T helper 1 and T helper 2 cells are pathogenic in an antigen-specific model of colitis. J Exp Med 2002;195:71-84.

86. Rutgeerts P, Geboes K. Understanding inflammatory bowel disease - the clinician's perspective. Eur J Surg Suppl 2001;586:66-72.

87. Desreumaux P, Brandt E, Gambiez L, et al. Distinct cytokine patterns in early and chronic ileal lesions of Crohn’s disease. Gastroenterology 1997;113:118-126.

88. Reuter BK, Pizarro TT. Commentary: the role of the IL-18 system and other members of the IL-1R/TLR superfamily in innate mucosal immunity and the pathogenesis of inflammatory bowel disease: friend or foe? Eur J Immunol 2004;34:2347-2355.

89. Keates AC, Castagliuolo I, Cruickshank WW, et al. Interleukin 16 is up-regulated in Crohn’s disease and participates in TNBS colitis in mice. Gastroenterology 2000;119:972-982.

90. Neurath MF, Weigmann, B, Finotto S, et al. The transcription factor T-bet regulates mucosal T cell activation in experimental colitis and Crohn’s disease. J Exp Med 2002;195:1129-1143.

91. Breese EJ, Michie CA, Nicholls SW, et al. Tumor necrosis factor alpha-producing cells in the intestinal mucosa of children with inflammatory bowel disease. Gastroenterology 1994;106:1455-1466.

92. Marini M, Bamias G, Rivera-Nieves J, et al. TNF-alpha neutralization ameliorates the severity of murine Crohn’s-like ileitis by abrogation of intestinal epithelial cell apoptosis. Proc Natl Acad Sci U S A 2003;100:8366-8371.

93. Monteleone G, MacDonald TT. Manipulation of cytokines in the management of patients with inflammatory bowel disease. Ann Med 2000;32:552-560.

94. Braegger CP, Nicholls S, Murch SH, et al. Tumour necrosis factor alpha in stool as a marker of intestinal inflammation. Lancet 1992;339:89-91.

95. Bamias G, Martin C 3rd, Marini M, et al. Expression, localization, and functional activity of TL1A, a novel Th1-polarizing cytokine in inflammatory bowel disease. J Immunol 2003;171:4868-4874.

96. D'Odorico A, Bortolan S, Cardin R, et al. Reduced plasma antioxidant concentrations and increased oxidative DNA damage in inflammatory bowel disease. Scand J Gastroenterol 2001;36:1289-1294.

97. Reimund JM, Hirth C, Koehl C, et al. Antioxidant and immune status in active Crohn’s disease. A possible relationship. Clin Nutr2000;19:43-48.

98. Sampietro GM, Cristaldi M, Cervato G, et al. Oxidative stress, vitamin A and vitamin E behaviour in patients submitted to conservative surgery for complicated Crohn’s disease. Dig Liver Dis 2002;34:696-701.

99. Wendland BE, Aghdassi E, Tam C, et al. Lipid peroxidation and plasma antioxidant micronutrients in Crohn disease. Am J Clin Nutr 2001;74:259-264.

100. Levy E, Rizwan Y, Thibault L, et al. Altered lipid profile, lipoprotein composition, and oxidant and antioxidant status in pediatric Crohn disease. Am J Clin Nutr 2000;71:807- 815.

101. Kruidenier L, Kuiper I, Lamers CB, Verspaget HW. Intestinal oxidative damage in inflammatory bowel disease: semi-quantification, localization, and association with mucosal antioxidants. J Pathol 2003:201:28-36.

102. Irvine EJ, Marshall JK. Increased intestinal permeability precedes the onset of Crohn’s disease in a subject with familial risk. Gastroenterology 2000;119:1740-1744.

103. Secondulfo M, de Magistris L, Fiandra R, et al. Intestinal permeability in Crohn’s disease patients and their first degree relatives. Dig Liver Dis 2001;33:680-685.

104. Breslin NP, Nash C, Hilsden RJ, et al. Intestinal permeability is increased in a proportion of spouses of patients with Crohn’s disease. Am J Gastroenterol 2001;96:2934-2938.

105. Soderholm JD, Olaison G, Lindberg E, et al. Different intestinal permeability patterns in relatives and spouses of patients with Crohn’s disease: an inherited defect in mucosal defence? Gut 1999;44:96-100.

106. Zamora SA, Hilsden RJ, Meddings JB, et al. Intestinal permeability before and after ibuprofen in families of children with Crohn’s disease. Can J Gastroenterol 1999;13:31-36.

107. Soderholm JD, Peterson KH, Olaison G, et al. Epithelial permeability to proteins in the noninflamed ileum of Crohn’s disease?Gastroenterology 1999;117:65-72.

108. Poritz LS, Garver KI, Tilberg AF, Koltun WA. Tumor necrosis factor alpha disrupts tight junction assembly. J Surg Res 2004;116:14-18.

109. Ma TY, Iwamoto GK, Hoa NT, et al. TNFalpha- induced increase in intestinal epithelial tight junction permeability requires NF-kappa B activation. Am J Physiol Gastrointest Liver Physiol 2004;286:G367-G376.

110. Wild GE, Waschke KA, Bitton A, Thomson AB. The mechanisms of prednisone inhibition of inflammation in Crohn’s disease involve changes in intestinal permeability, mucosal TNF alpha production and nuclear factor kappa B expression. Aliment Pharmacol Ther2003;18:309-317.

111. Suenaert P, Bulteel V, Lemmens L, et al. Antitumor necrosis factor treatment restores the gut barrier in Crohn’s disease. Am J Gastroenterol 2002;97:2000-2004.

112. Iwata M, Nakano H, Matsuura Y, et al. Intestinal permeability in Crohn’s disease and effects of elemental dietary therapy. Nippon Shokakibyo Gakkai Zasshi 2001;98:636-643. [Article in Japanese]

113. Wyatt J, Vogelsang H, Hubl W, et al. Intestinal permeability and the prediction of relapse in Crohn’s disease. Lancet 1993;341:1437-1439.

114. Malin M, Isolauri E, Pikkarainen P, et al. Enhanced absorption of macromolecules. A secondary factor in Crohn’s disease. Dig DisSci 1996;41:1423-1428.

115. Arnott ID, Kingstone K, Ghosh S. Abnormal intestinal permeability predicts relapse in inactive Crohn disease. Scand J Gastroenterol 2000;35:1163-1169.

116. D'Inca R, Di Leo V, Corrao G, et al. Intestinal permeability test as a predictor of clinical course in Crohn’s disease. Am J Gastroenterol 1999;94:2956-2960.

117. Jorgensen J, Ranlov PJ, Bjerrum PJ, et al. Is an increased intestinal permeability a valid predictor of relapse in Crohn disease? Scand J Gastroenterol 2001;36:521-527.

118. Adenis A, Colonbel JF, Lecouffe P, et al. Increased pulmonary and intestinal permeability in Crohn’s disease. Gut 1992;33:678-682.

119. Puspok A, Oberhuber G, Wyatt J, et al. Gastroduodenal permeability in Crohn’s disease. Eur J Clin Invest 1998;28:67-71.

120. Wyatt J, Oberhuber G, Pongratz S, et al. Increased gastric and intestinal permeability in patients with Crohn’s disease. Am J Gastroenterol 1997;92:1891-1896.

121. Danese S, de la Motte C, Fiocchi C. Platelets in inflammatory bowel disease: clinical, pathogenic, and therapeutic implications. Am J Gastroenterol 2004;99:938-945.

122. Collins CE, Rampton DS, Rogers J, Williams NS. Platelet aggregation and neutrophil sequestration in the mesenteric circulation in inflammatory bowel disease. Eur J Gastroenterol Hepatol 1997;9:1213-1217.

123. Papa A, De Stefano V, Danese S, et al. Hyperhomocysteinemia and prevalence of polymorphisms of homocysteine metabolism - related enzymes in patients with inflammatory bowel disease. Am J Gastroenterol 2001;96:2677-2682.

124. Romagnuolo F, Fedorak RN, Dias VC, et al. Hyperhomocysteinemia and inflammatory bowel disease: prevalence and predictors in a cross-sectional study. Am J Gastroenterol 2001;96:2143-2149.

125. Chowers Y, Sela B, Holland R, et al. Increased levels of homocysteine in patients with Crohn’s disease are related to folate levels. Am J Gastroenterol 2000;95:3498-3502.

126. Younes-Mhenni S, Derex L, Berruyer M, et al. Large-artery stroke in a young patient with Crohn’s disease. Role of vitamin B6 deficiency- induced hyperhomocysteinemia. JNeurol Sci 2004;221:113-115.

127. O'Morain C, Smethurst P, Levi J, Peters TJ. Subcellular fractionation of rectal biopsy homogenates from patients with inflammatory bowel disease. Scand J Gastroenterol 1985;20:209-214.

128. Cogswell PC, Kashatus DF, Keifer JA, et al. NF-kappa B and I kappa B alpha are found in the mitochondria. Evidence for regulation of mitochondrial gene expression by NF-kappa B. J Boil Chem 2003;278:2963-2968.

129. Restivo NL, Srivastava MD, Schafer IA, Hoppel CL. Mitochondrial dysfunction in a patient with Crohn disease: possible role in pathogenesis. J Pediatr Gastroenterol Nutr2004;38:534-538.

130. Bjarnason I, Williams P, So A, et al. Intestinal permeability and inflammation in rheumatoid arthritis: effects of non-steroidal anti-inflammatory drugs. Lancet 1984;2:1171-1174.

131. Bjarnason I, Hayllar J, MacPherson AJ, Russel AS. Side effects of nonsteroidal anti-inflammatory drugs on the small and large intestine in humans. Gastroenterology 1993;104:1832- 1847.

132. Davies NM. Review article: nonsteroidal antiinflammatory drug-induced gastrointestinal permeability. Aliment Pharmacol Ther1998;12:303-320.

133. Halter F, Tarnawski AS, Schmassmann A, Peskar BM. Cyclooxygenase 2-implications on maintenance of gastric mucosal integrity and ulcer healing: controversial issues and perspectives.Gut 2001;49:443-453.

134. Jackson LM, Wu KC, Mahida YR, et al. Cyclooxygenase (COX) 1 and 2 in normal, inflamed, and ulcerated human gastric mucosa.Gut 2000;47:762-770.

135. Sibbald B. Rofecoxib (Vioxx) voluntarily withdrawn from market. CMAJ 2004;171:1027-1028.

136. Summers RW, Switz DM, Sessions JT Jr, et al. National Cooperative Crohn’s Disease Study: results of drug treatment. Gastroenterology 1979;77:847-869.

137. Krogh Jensen M, Ekelund S, Svendsen L. Folate and homocysteine status and haemolysis in patients treated with sulphasalazine for arthritis. Scand J Clin Lab Invest 1996;56:421-429.

138. Hanauer SB, Stromberg U. Oral Pentasa in the treatment of active Crohn’s disease: a meta-analysis of double-blind, placebocontrolled trials. Clin Gastroenterol Hepatol2004;2:379-388.

139. Drug Facts and Comparisons. 58th ed. St. Louis, MO: Wolters Kluwer Health; 2004: 399.

140. Escher JC. Budesonide versus prednisolone for the treatment of active Crohn’s disease in children: a randomized, double-blind, controlled, multicenter trial. Eur J Gastroenterol Hepatol 2004;16:47-54.

141. Maantzaris GJ, Petraki K, Sfakianakis M, et al. Budesonide versus mesalamine for maintaining remission in patients refusing other immunomodulators for steroid dependent Crohn’s disease. Clin Gastroenterol Hepatol 2003;1:122-128.

142. de Jong DJ, Goullet M, Naber TH. Side effects of azathioprine in patients with Crohn’s disease. Eur J Gastroenterol Hepatol2004;16:207-212.

143. Gombar VK, Enslein K, Blake BW, Einstein K. Carcinogenicity of azathioprine: an S-AR investigation. Mutat Res 1993;302:7-12.

144. Goldstein ED, Marion JF, Present DH. 6- mercaptopurine is effective in Crohn’s disease without concomitant steroids. Inflamm Bowel Dis 2004;10:79-84.

145. Soon SY, Ansari A, Yaneza M, et al. Experience with the use of low-dose methotrexate for inflammatory bowel disease. Eur J Gastroenterol Hepatol 2004;16:921-926.

146. Drug Facts and Comparisons. 58th ed. St. Louis, MO: Wolters Kluwer Health; 2004:1898.

147. Egan LJ, Sandborn WJ. Methotrexate for inflammatory bowel disease: pharmacology and preliminary results. Mayo Clin Proc1996;71:69-80.

148. Scribano M, Prantera C. Review article: medical treatment of moderate to severe Crohn’s disease. Aliment Pharmacol Ther2003;17:S23-S30.

149. Ten Hove T, van Montfrans C, Peppelenbosch MP, et al. Infliximab treatment induces apoptosis of lamina propria T lymphocytes in Crohn’s disease. Gut 2002;50:206-211.

150. Targan SR, Hanauer SB, Van Deventer SJ, et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn’s disease. N Engl J Med1997;337:1029-1035.

151. Hanauer SB, Feagan BG, Lichtenstein GR, et al. Maintenance infliximab for Crohn’s disease: the ACCENT I randomized trial.Lancet 2002;359:1541-1549.

152. Cheifetz A, Smedley M, Martin S, et al. The incidence and management of infusion reactions to infliximab: a large center experience.Am J Gastroenterol 2003;98:1315-1324.

153. Keane J, Gerson S, Wise RP, et al. Tuberculosis associated with infliximab, a tumor necrosis factor alpha neutralizing agent. NEngl J Med 2001;345:1098-1104.

154. Colombel JF, Loftus EV Jr, Tremaine WJ, et al. The safety profile of infliximab in patients with Crohn’s disease: the Mayo clinic experience in 500 patients. Gastroenterology2004;126:19-31.

155. Feagan BG, Sandborn WJ, Baker J, et al. A randomized, double-blind, placebo-controlled, multi-center trial of the engineered human antibody to TNF (CDP571) for steroid sparing and maintenance of remission in patients with steroid-dependent Crohn’s disease. Gastroenterology2000;118:A655.

156. Winter T, Wright J, Ghosh S, et al. Intravenous CDP870, a humanized anti-TNF antibody fragment, in patients with active Crohn’s disease -- an exploratory study. Gastroenterology 2003;124:A377.

157. Rutgeerts P, Lemmens L, Van Assche G, et al. Treatment of active Crohn’s disease with onercept (recombinant human soluble p55 tumour necrosis factor receptor): results of a randomized, open-label, pilot study. Aliment Pharmacol Ther 2003;17:185-192.

158. Sandborn WJ, Hanauer S, Loftus EV, et al. An open-label study of the human anti-TNF monoclonal antibody adalimumab in subjects with prior loss of response or intolerance to infliximab for Crohn’s disease. Gastroenterology2004;126:A53-A54.

159. Gordon FH, Lai CW, Hamilton MI, et al. A randomized placebo-controlled trial of a humanized monoclonal antibody to alpha4 integrin in active Crohn’s disease. Gastroenterology 2001;121:268-274.

160. Rutgeerts P, Colombel J, Enns R, et al. Subanalyses from a phase 3 study on the evaluation of natalizumab in active Crohn’s disease therapy-1(ENACT-1). Gut2003;52:Suppl VI:A239.

161. Feagan BG, Greenberg G, Wild G, et al. Efficacy and safety of a humanized alpha4beta7 antibody in active Crohn’s disease. Gastroenterology 2003;124:A25-A26.

162. Sandborn WJ, Faubion WA. Biologics in inflammatory bowel disease: how much progress have we made? Gut 2004;53:1366- 1373.

163. Kuroki F, Iida M, Tominaga M, et al. Multiple vitamin status in Crohn’s disease. Dig Dis Sci1993;38:1614-1618.

164. Rath HC, Caesar I, Roth M, Scholmerich J. Nutritional deficiencies and complications in chronic inflammatory bowel disease. Med Klin 1998;93:6-10. [Article in German]

165. Geerling BJ, Badart-Smook A, Stockbrugger RW, Brummer RJ. Comprehensive nutritional status in patients with long-standing Crohn disease currently in remission. Am J Clin Nutr1998;67:919-926.

166. Geerling BJ, Badart-Smook A, Stockbrugger RW, Brummer RJ. Comprehensive nutritional status in recently diagnosed patients with inflammatory bowel disease compared with population controls. Eur J Clin Nutr 2000;54:514-521.

167. Imes S, Pinchbeck BR, Dinwoodie A, et al. Iron, folate, vitamin B-12, zinc, and copper status in out-patients with Crohn’s disease: effect of diet counseling. J Am Diet Assoc1987;87:928-930.

168. Sentongo TA, Semaeo EJ, Stettler N, et al. Vitamin D status in children, adolescents, and young adults with Crohn disease. Am J Clin Nutr 2002;76:1077-1081.

169. Dibble JB, Sheridan P, Losowsky MS. A survey of vitamin D deficiency in gastrointestinal and liver disorders. Quarterly J Med 1984;209:119-134.

170. Abreu MT, Kantorovich V, Vasiliauskas EA, et al. Measurement of vitamin D levels in inflammatory bowel disease patients reveals a subset of Crohn’s disease patients with elevated 1,25-dihydroxyvitamin D and low bone mineral density. Gut 2004;53:1129-1136.

171. Schoon EJ, Muller MC, Vermeer C, et al. Low serum and bone vitamin K status in patients with longstanding Crohn’s disease; another pathogenetic factor of osteoporosis in Crohn’s disease? Gut 2001;48:473-477.

172. Steger GG, Mader RM, Vogelsang H, et al. Folate absorption in Crohn’s disease. Digestion1994;55:234-238.

173. Imes S, Dinwoodie A, Walker K, et al. Vitamin C status in 137 outpatients with Crohn’s disease. J Clin Gastroenterol 1986;8:443-446.

174. Hughes RG, Williams N. Leucocyte ascorbic acid in Crohn’s disease. Digestion1978;17:272-274.

175. Linaker BD. Scurvy and vitamin C deficiency in Crohn’s disease. Postgrad Med J1979;55:26-29.

176. Gerson CD, Fabry EM. Ascorbic acid deficiency and fistula formation in regional enteritis. Gastroenterol 1974;67:428-433.

177. Pettit SH, Irving MH. Does local intestinal ascorbate deficiency predispose to fistula formation in Crohn’s disease. Dis Col Rect1987;30:552-557.

178. Pettit SH, Shaffer JL, Johns W, et al. Ascorbic acid absorption in Crohn’s disease. Dig Dis Sci1989;34:559-566.

179. Kuroki F, Iida M, Tominaga M, et al. Is vitamin E depleted in Crohn’s disease at initial diagnosis? Dig Dis 1994;12:248-254.

180. Main A, Mills PR, Russell RI, et al. Vitamin A deficiency in Crohn’s disease. Gut1983;24:1169-1175.

181. Janczewska I, Bartnik W, Butruk R, et al. Metabolism of vitamin A in inflammatory bowel disease. Hepato Gastroenterol 1991;38:391-395.

182. Bousvaros A, Zurakowski D, Duggan C, et al. Vitamins A and E serum levels in children and young adults with inflammatory bowel disease: effect of disease activity. J Pediatr Gastroenterol Nutr 1998;26:129-135.

183. Imes S, Pinchbeck B, Dinwoodie A, et al. Vitamin A status in 137 patients with Crohn’s disease. Digestion 1987;37:166-170.

184. Rumi G Jr, Szabo I, Vincze A, et al. Decrease of serum carotenoids in Crohn’s disease. J Physiol 2000;94:159-161.

185. Schoelmerich J, Becher MS, Hoppe-Seyler P, et al. Zinc and vitamin A deficiency in patients with Crohn’s disease is correlated with activity but not with localization or extent of the disease. Hepatogastroenterology 1985;32:34- 38.

186. Nakamura T, Higashi A, Takano S, et al. Zinc clearance correlates with clinical severity of Crohn’s disease: a kinetic study. Dig Dis Sci1988;33:1520-1524.

187. Kruis W, Rindfleisch GE, Weinzieri M. Zinc deficiency as a problem in patients with Crohn’s disease and fistula formation.Hepatogastroenterology 1985;32:133-134.

188. Brody L, Powell S, Collier KP, et al. Increased oxidative stress and decreased antioxidant defenses in mucosa of inflammatory bowel disease. Dig Dis Sci 1996;41:2078-2086.

189. Ringstad J, Kildero S, Thomassen Y. Serum selenium, copper, and zinc concentrations in Crohn’s disease and ulcerative colitis. Scand J Gastroenterol 1993;28:605-608.

190. Ojuawo A, Keith L. The serum concentrations of zinc, copper and selenium in children with inflammatory bowel disease. Cent Afr J Med2002;48:116-119.

191. Lomer M, Kodjabashia K, Hutchinson C, et al. Intake of dietary iron is low in patients with Crohn’s disease: a case-control study. Br J Nutr 2004;91:141-148.

192. Halliwell B, Gutteridge JM. Oxygen free radicals and iron in relation to biology and medicine; some problems and concepts. Arch Biochem Biophys 1986;246:501-514.

193. Erichsen K, Hausken T, Ulvik RJ, et al. Ferrous fumarate deteriorated plasma antioxidant status in patients with Crohn disease.Scand J Gastroenterol 2003;38:543-548.

194. Mayberry JF, Rhodes J, Allan R, et al. Diet in Crohn’s disease. Dig Dis Sci 1981;26:444-448.

195. Reif S, Klein I, Lubin F, et al. Pre-illness dietary factors in inflammatory bowel disease.Gut 1997;40:754-760.

196. Tragnone A, Valpiani D, Miglio F, et al. Dietary habits as risk factors for inflammatory bowel disease. Eur J Gastroenterol Hepatol1995;7:47-51.

197. Persson PG, Ahlbom A, Hellers G. Diet and inflammatory bowel disease: a case-control study. Epidemiology 1992;3:47-52.

198. Khursheed NJ. Clinical nutrition: 6. Management of nutritional problems of patients with Crohn’s disease. Can Med J 2002;1166:913- 918.

199. American Society for Parenteral and Enteral Nutrition (ASPEN), Board of Directors. Guidelines for the use of enteral nutrition in the adult patient. J Enteral Parenteral Nutr 1987;11:435-439.

200. Murch SH, Walker-Smith JA. Nutrition in inflammatory bowel disease. Baillieres Clin Gastroenterol 1998;12:719-738.

201. Russell RI. Elemental diets. Gut 1975;16:68- 79.

202. Beattie RM, Schiffrin EJ, Donnet-Hughes A, et al. Polymeric nutrition as the primary therapy in children with small bowel Crohn’s disease.Aliment Pharmacol Ther 1994;8:609-615.

203. Mansfield JC, Giaffer MH, Holdsworth CD. Controlled trial of oligopeptide versus amino acid diet in treatment of active Crohn’s disease. Gut 1995;36:60-66.

204. Gonzalez-Huix F, de Leon R, Fernandez- Banares F, et al. Polymeric enteral diets as primary treatment of active Crohn’s disease: a prospective steroid controlled trial. Gut1993;34:778-782.

205. Gorard DA, Hunt JB, Payne-James JJ, et al. Initial response and subsequent course of Crohn’s disease treated with elemental diet or prednisolone. Gut 1993;34:1198-1202.

206. Malchow H, Steinhardt HJ, Lorenz-Meyer H, et al. Feasibility and effectivenesss of a defined-formula diet regimen in treating active Crohn’s disease. European Cooperative Crohn’s Disease Study III. Scand J Gastroenterol 1990;25:235-244.

207. O'Morain C, Segal AW, Levi AJ. Elemental diet as primary treatment of acute Crohn’s disease: a controlled trial. Br Med J (Clin Res Ed) 1984;288:1859-1862.

208. Riordan AM, Hunter JO, Cowan RE, et al. Treatment of active Crohn’s disease by exclusion diet: East Anglian multicentre controlled trial. Lancet 1993;342:1131-1134.

209. Zoli G, Care M, Parazza M, et al. A randomized controlled study comparing elemental diet and steroid treatment in Crohn’s disease.Aliment Pharmacol Ther 1997;11:735-740.

210. Azcue M, Rashid M, Griffiths A, Pencharz PB. Energy expenditure and body composition in children with Crohn’s disease: effect of enteral nutrition and treatment with prednisolone. Gut1997;41:203-208.

211. Beattie RM, Bentsen BS, MacDonald TT. Childhood Crohn’s disease and the efficacy of enteral diets. Nutrition 1998;14:345-350.

212. Shoda R, Matsueda K, Yamato S, Umeda N. Epidemiological analysis of Crohn disease in Japan: increased dietary intake of n-6 polyunsaturated fatty acids and animal protein relates to the increased incidence of Crohn disease in Japan. Am J Clin Nutr 1996;63:741-745.

213. Bamba T, Shimoyama T, Sasaki M, et al. Dietary fat attenuates the benefits of an elemental diet in active Crohn’s disease: a randomized, controlled trial. Eur J Gastroenterol Hepatol 2003;15:151-157.

214. Middleton SJ, Rucker JT, Kirby GA, et al. Long-chain triglycerides reduce the efficacy of enteral feeds in patients with active Crohn’s disease. Clin Nutr 1995;14:229-236.

215. Gassull MA, Fernandez-Banares F, Cabre E, et al. Fat composition may be a clue to explain the therapeutic effect of enteral nutrition in Crohn’s disease: results of a double-blind randomized multicenter European trial. Gut2002;51:164-168.

216. Levenstein S, Prantera C, Luzi C, D'Ubaldi A. Low residue or normal diet in Crohn’s disease: a prospective controlled study in Italian patients. Gut 1985;26:989-993.

217. Jones VA, Workman E, Freeman AH, et al. Crohn’s disease: maintenance of remission by diet. Lancet 1985;2:177-180.

218. Ritchie JK, Wadsworth J, Lennard-Jones JE, Rogers E. Controlled multicenter therapeutic trial of an unrefined carbohydrate, fibre rich diet in Crohn’s disease. Br Med J1987;295:517-520.

219. Heaton KW, Thornton JR, Emmett PM. Treatment of Crohn’s disease with an unrefined carbohydrate, fibre-rich diet. Br Med J1979;2:764-766.

220. Pearson M, Teahon K, Levi AJ, Bjarnason I. Food intolerance and Crohn’s disease. Gut1993;34:783-787.

221. Boudeau J, Glasser AL, Julien S, et al. Inhibitory effect of probiotic Escherichia colistrain Nissle 1917 on adhesion to and invasion of intestinal epithelial cells by adherentinvasiveE. coli strains from isolated patients with Crohn’s disease. Aliment Pharmacol Ther2003;18:45-56.

222. Mattar AF, Teitelbaum DH, Drongowski RA, et al. Probiotics up-regulate MUC-2 mucin gene expression in a Caco-2 cell culture model. Pediatr Surg Int 2002;18:586-590.

223. Malin M, Suomalainen H, Saxelin M, Isolauri E. Promotion of IgA immune response in patients with Crohn’s disease by oral bacteriotherapy with Lactobacillus GG. Ann Nutr Metab 1996;40:137-145.

224. Borreul N, Carol M, Casellas F, et al. Increased mucosal tumour necrosis factor alpha production in Crohn’s disease can be downregulated ex vivo by probiotic bacteria.Gut 2002;51:659-664.

225. Plein K, Hotz J. Therapeutic effects ofSaccharomyces boulardii on mild residual symptoms in a stable phase of Crohn’s disease with special respect to chronic diarrhea -- a pilot study. Z Gastroenterol 1993;31:129-134.

226. Guslandi M, Mezzi G, Sorghi M, Testoni PA.Saccharomyces boulardii in maintenance treatment of Crohn’s disease. Dig Dis Sci2000;45:1462-1464.

227. Malchow HA. Crohn’s disease and Escherichia coli. A new approach in therapy to maintain remission of colonic Crohn’s disease?J Clin Gastroenterol 1997;25:653-658.

228. Gupta P, Andrew H, Kirschner BS, Guandalini S. Is Lactobacillus GG helpful in children with Crohn’s disease? Results of a preliminary, open-label study. J Pediatr Gastroenterol Nutr 2000;31:453-457.

229. Prantera C, Scribano ML, Falasco G, et al. Ineffectiveness of probiotics in preventing recurrence after curative resection for Crohn’s disease: a randomized controlled trial with Lactobacillus GG. Gut 2002;51:405-409.

230. Kruidenier L, Kuiper I, van Duijn W, et al. Differential mucosal expression of three superoxide dismutase isoforms in inflammatory bowel disease. J Pathol 2003;201:7-16.

231. Kruidenier L, Kuiper I, van Duijn W, et al. Imbalance secondary mucosal antioxidant response in inflammatory bowel disease. J Pathol 2003;201:17-27.

232. Reimund JM, Allison AC, Muller CD, et al. Antioxidants inhibit the in vitro production of inflammatory cytokines in Crohn’s disease and ulcerative colitis. Eur J Clin Invest1998;28:145-150.

233. Iantomasi T, Marraccini P, Favilli F, et al. Oral absorption studies in patients with CD are warranted. Biochem Med Metab Bio1994;53:87-91.

234. Aghkassi E, Wendland BE, Steinhart H, et al. Antioxidant vitamin supplementation in Crohn’s disease decreases oxidative stress: a randomized controlled trial. Am J Gastroenterol 2003;98:348-353.

235. Skogh M, Sundquist T, Tagesson C. Vitamin A in Crohn’s disease (correspondence). Lancet1980;315:766.

236. Norrby S, Sjodahl R, Tagesson C. Ineffectiveness of vitamin A therapy in severe Crohn’s disease. Acta Chir Scand 1985;151:465-468.

237. Wright JP, Mee AS, Parfitt P, et al. Vitamin Atherapy in patients with Crohn’s disease. Gastroenterology 1985;88:512-514.

238. Kuroki F, Iida M, Matsumoto T, et al. Serum n3 polyunsaturated fatty acids are depleted in Crohn’s disease. Dig Dis Sci 1997;42:1137- 1141.

239. Alzoghaibi MA, Walsh SW, Willey A, et al. Linoleic acid induces interleukin-8 production by Crohn’s human intestinal smooth muscle cells via arachidonic acid metabolites. Am J Physiol Gastrointest Liver Physiol 2004;286:G528-G537.

240. Tsujikawa T, Satoh J, Uda K, et al. Clinical importance of n-3 fatty acid-rich diet and nutritional education for the maintenance of remission in Crohn’s disease. J Gastroenterol2000;35:99-104.

241. Lorenz R, Weber PC, Szimnau P, et al. Supplements with n-3 fatty acids from fish oil in chronic inflammatory bowel disease -- a randomized, placebo-controlled, double-blind cross-over trial. J Intern Med 1989;225:225- 232.

242. Hillier K, Jewell R, Dorrell L, Smith CL. Incorporation of fatty acids from fish oil and olive oil into colonic mucosal lipids and effects upon eicosanoid synthesis in inflammatory bowel disease. Gut 1991;32:1151-1155.

243. Lorenz-Meyer H, Bauer P, Nicolay C, et al. Omega-3 fatty acids and low carbohydrate diet for maintenance of remission in Crohn’s disease. A randomized controlled multicenter trial. Study Group Members (German Crohn’s Disease Study Group). Scand J Gastroenterol 1996;31:778-785.

244. Belluzzi A, Brignola C, Campieri M, et al. Effect of an enteric-coated fish-oil preparation on relapses in Crohn’s disease. N Engl J Med1996;334:1557-1560.

245. Arslan G, Brunborg LA, Froyland L, et al. Effects of duodenal seal oil administration in patients with inflammatory bowel disease.Lipids 2002;37:935-940.

246. Segain JP, de la Bletiere DR, Bourreille A, et al. Butyrate inhibit inflammatory responses through NFkappaB inhibition: implications for Crohn’s disease. Gut 2000;47:397-403.

247. Coeffier M, Marion R, Ducrotte P, Dechelotte P. Modulating effect of glutamine in IL-1betainduced cytokine production by human gut.Clin Nutr 2003;22:407-413.

248. Hond ED, Hiele M, Peeters M, et al. Effect of long-term oral glutamine supplements on small intestinal permeability in patients with Crohn’s disease. JPEN J Parenter Enteral Nutr1999;23:7-11.

249. Akobeng AK, Miller CV, Stanton J, et al. Double-blind randomized controlled trial of glutamine-enriched polymeric diet in the treatment of active Crohn’s disease. J Pediatr Gastroenterol Nutr 2000;30:78-84.

250. Akobeng AK, Miller CV, Thomas AG, Richmond K. Glutamine supplementation and intestinal permeability in Crohn’s disease.JPEN J Parenter Enteral Nutr 2000;24:196.

251. Akobeng AK, Miller CV, Hall CM, Thomas AG. Low serum concentrations of insulin-like growth factor-I in children with active Crohn disease. Scand J Gastroenterol 2002;12:1422- 1427.

252. Goodman MJ, Kent PW, Truelove SC. Glucosamine synthetase activity of the colonic mucosa in ulcerative colitis and Crohn’s disease. Gut 1977;18:219-228.

253. Salvatore S, Heuschkel R, Tomlin S, et al. A pilot study of N-acetylglucosamine, a nutritional substrate for glycosaminoglycan synthesis, in paediatric chronic inflammatory bowel disease. Aliment Pharmacol Ther2000;14:1567-1579.

254. Srinivasan P, Libbus B. Mining MEDLINE for implicit links between dietary substances and diseases. Bioinformatics 2004;20:1290-1296.

255. Ammon HP, Mack T, Singh GB, Safayhi H. Inhibition of leukotriene B4 formation in rat peritoneal neutrophils by an ethanolic extract of the gum resin exudate of Boswellia serrata.Planta Med 1991;57:203-207.

256. Gerhardt H, Seifert F, Buvari P, et al. Therapy of active Crohn disease with Boswellia serrata extract H 15. Z Gastroenterol 2001;39:11-17. [Article in German]

257. Zhou H, Mineshita S. The effect of berberine chloride in experimental colitis in rats in vivo and in vitro. J Pharmacol Exp Ther2000;294:822-829.

258. Straub RH, Vogl D, Gross V, et al. Association of humoral markers of inflammation and dehydroepiandrosterone sulfate or cortisol serum levels in patients with inflammatory bowel disease. Am J Gastroenterol 1998;93:2197-2202.

259. Straub RH, Lehle K, Herfarth H, et al. Dehydroepiandrosterone in relation to other adrenal hormones during an acute inflammatory stressful disease state compared with chronic inflammatory disease: role of interleukin-6 and tumour necrosis factor. Eur J Endocrinol 2002;146:365-367.

260. Andus T, Klebl F, Rogler G, et al. Patients with refractory Crohn’s disease or ulcerative colitis respond to dehydroepiandrosterone: a pilot study. Aliment Pharmacol Ther 2003;17:409- 414.

261. Robinson RJ, Iqbal SJ, Al-Azzawi F, et al. Sex hormone status and bone metabolism in men with Crohn’s disease. Aliment Pharmacol Ther 1998;12:21-25.

262. Lamb EJ, Wong T, Smith DJ, et al. Metabolic bone disease is present at diagnosis in patients with inflammatory bowel disease. Aliment Pharmacol Ther 2002;16:1895-1902.

263. Bjarnson I, MacPherson A, Mackintosh C, et al. Reduced bone density in patients with inflammatory bowel disease. Gut 1997;40:228- 233.

264. Vestergaard P, Krogh K, Rejnmark L, et al. Fracture risk is increased in Crohn’s disease, but not in ulcerative colitis. Gut 2000;46:176- 181.

265. Dear KL, Compston JE, Hunter JO. Treatments for Crohn’s disease that minimize steroid doses are associated with a reduced risk of osteoporosis. Clin Nutr 2001;20:541-546.

266. Card T, West J, Hubbard R, Logan RF. Hip fractures in patients with inflammatory bowel disease and their relationship to corticosteroids use: a population based cohort study. Gut2004;53:251-255.

267. Nanes MS. TNF-alpha: molecular and cellular mechanisms in skeletal pathology. Gene2003;321:1-15.

268. Jess T, Winther KV, Munkholm P, et al. Intestinal and extra-intestinal cancer in Crohn’s disease: follow-up of a population based cohort in Copenhagen County, Denmark.Aliment Pharmacol Ther 2004;19:287- 293.

269. Eaden J. Review article: colorectal carcinoma and inflammatory bowel disease. Aliment Pharmacol Ther 2004;20:S24-S30.

270. National Toxicology Program. NTP toxicology and carcinogenesis studies of salicylazosulfapyridine (CAS No. 599-79-1) in F344/N rats and B6C3F1 mice (Gavage Studies). Natl Toxicol Program Tech Rep Ser1997;457:1-327.

271. Donaldson LB. Crohn’s disease: - its gynecologic aspect.Am J Obstet Gynecol1978;131:196-202.

272. Hudson M, Flett G, Sinclair TS, et al. Fertility and pregnancy in inflammatory bowel disease.Int J Gynaecol Obstet 1997;58:229-237.

273. Farthing MJ, Dawson AM. Impaired semen quality in Crohn’s disease - drugs, ill health, or undernutrition? Scand J Gastroenterol1983;18:57-60.

274. Karbach U, Ewe K, Schramm P. Quality of semen in patients with Crohn’s disease. ZGastroenterol 1982;20:314-320. [Article in German]

275. Schramm P, Ewe K, Karbach U. Spermatogram evaluation in cases with Crohn's disease. Andrologia 1981;13:352-358. [Article in German]

276. El-Tawil AM. Zinc deficiency in men with Crohns disease may contribute to poor sperm function and male infertility. Andrologia 2003;35:337-341.

277. Karaca C, Pinarbasi B, Danalioglu A, et al. Liver abscess as a rare complication of Crohns disease: a case report. Turk J Gastroenterol 2004;15:45-48.

278. Molina Infante J, Barnares Canizares R, Gomez Camarero J, Perez Calle JL. Liver abscess and Crohns disease. Report of 3 cases.Gastroenterol Hepatol 2004;27:317-319.

279. Manfredi R, Coronado OV, Marinacci G, et al. Crohn's disease, rare association with selective IgA immunodeficiency and development of life-threatening bacterial infections. Scand J Infect Dis 2004;36:523-524.


Call 1-877-240-7528 • Mon-Fri 9am-5pm PST
P.O. Box 927747 ~ San Diego ~ California ~ 92192 ~ USA
Home | About Us | Quick Product Links | Search | Help